At a glance
ClinicalIndex Comparison RecordN/ACompleted· 408 enrolled
Drug / intervention
Nab-Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-interventional Study of Nab-paclitaxel (Abraxane®) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)
In Brief
An observational study evaluating Nab-Paclitaxel and Carboplatin for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 408 participants across 1 site.
Detailed Summary
This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and quality of life (QoL) in patients with advanced NSCLC receiving the combination of nab-paclitaxel and carboplatin as first line palliative therapy in a real life setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesGermany
CollaboratorsBristol-Myers Squibb
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionDec 2019
Study CompletionJun 2021
TodayJul 2026
First PostedJun 15, 2016
Enrollment StartAug 29, 2016
Primary CompletionDec 7, 2019
Study CompletionJun 6, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.0 years ago
Interventions
Nab-Paclitaxeldrug
Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
Carboplatindrug
Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.